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Background: Weight loss is often difficult to achieve in individuals with type 2 diabetes and anti-obesity drugs are
often advocated to support dietary intervention. Despite the extensive use of centrally acting anti-obesity drugs,
there is little evidence of how they affect dietary composition. We investigated changes in energy intake and
dietary composition of macro- and micronutrients following therapy with the endocannabinoid receptor blocker,
rimonabant.
Methods: 20 obese patients with type 2 diabetes were studied before and after 6 months dietary intervention with
rimonabant. Dietary intervention was supervised by a diabetes dietician. Five-day food diaries were completed at
baseline and at 6 months and dietary analysis was performed using computer software (Dietplan 6).
Results: After 6 months, (compared with baseline) there were reductions in weight (107 ± 21Kg versus 112 ± 21,
p< 0.001, 4% body weight reduction), and improvements in HbA1c (7.4 ± 1.7 versus 8.0 ± 1.6%, p< 0.05) and HDL
cholesterol. Intake of energy (1589 ± 384 versus 2225 ± 1109 kcal, p< 0.01), carbohydrate (199 ± 74 versus
273 ± 194 g, p< 0.05), protein (78 ± 23 versus 98 ± 36 g, p< 0.05), fats (55 ± 18 versus 84 ± 39 g, p< 0.01) and
several micronutrients were reduced. However, relative macronutrient composition of the diet was unchanged.
Improvement in blood glucose was strongly correlated with a reduction in carbohydrate intake (r = 0.76, p< 0.001).
Conclusions: In obese patients with type 2 diabetes, rimonabant in combination with dietary intervention led to
reduced intake of energy and most macronutrients. Despite this, macronutrient composition of the diet was
unaltered. These dietary changes (especially carbohydrate restriction) were associated with weight loss and
favourable metabolic effects.
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Obesity is extremely common in type 2 diabetes and is a
major contributor to premature morbidity and mortality
[1,2]. Obesity results from an imbalance of energy intake
and energy expenditure and so any strategy to reduce
body weight must rely on either, a reduction in energy in-
take, an increase in energy expenditure or both. Super-
vised weight-loss through dietary intervention is therefore* Correspondence: jamie.smith2@nhs.net
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distribution, and reproduction in any mediumconsidered a cornerstone in the management of obese
individuals with type 2 diabetes [3]. However, most strat-
egies used to combat obesity have not yielded long-term
success and so there is increasing interest in the use and
development of pharmacological agents to tackle obesity
[4]. Centrally-acting anti-obesity drugs such as sibutra-
mine or the CB1 receptor antagonist rimonabant are con-
sidered to act principally by reducing appetite and/or
increasing satiety, thereby producing reduced energy in-
take [4,5]. For example, in the RIO-trial programme in-
volving obese subjects with type 2 diabetes and other
cardiovascular risk factors, rimonabant in combinationntral Ltd. This is an Open Access article distributed under the terms of the
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600 kcal was extensively studied in terms of weight, meta-
bolic and cardiovascular parameters [6]. However, despite
these large clinical trials and widespread clinical use there
is little evidence of how centrally acting anti-obesity drugs
specifically affect dietary composition in humans.
In the case of rimonabant, animal data suggest that
weight loss occurs not only because of reduced energy
intake, but also due to increased energy expenditure
through increased fat oxidation in adipose tissue [7]. In
addition, animal data also suggest that CB1 receptor an-
tagonism in the rat hypothalamus leads to a preferential
reduction in the intake of palatable fatty and sugary food
[8,9]. To date, these findings have not been demon-
strated in human studies. Because of concerns relating
to depression and suicidal risk, rimonabant’s license was
withdrawn by the European regulatory authorities in
2008 but there is still interest in this therapeutic class
with other agents in development [5].
In recent times there has been substantial interest in
the way macronutrient intake affects both weight and
glycemia in type 2 diabetes [3], especially the effects of
restricting carbohydrate intake [10-12]. Several studies
have reported benefits in terms of improved glucose
control when a low carbohydrate diet is compared with
conventional intake of carbohydrate [10,13-15] although
evidence is conflicting with not all studies demonstrating
these benefits [12,16].
The aim of this study was as follows:- [1] to assess
weight and metabolic changes following rimonabant
therapy in obese patients with type 2 diabetes; [2] to in-
vestigate in detail, changes in energy, macro- and micro-
nutrient intake following rimonabant therapy; and [3] to
investigate how changes in macronutrient intake (eg.
carbohydrate, fat) might influence changes in weight and
glycaemia.
Methods
Study design and subjects
Twenty subjects (age range 30-70 yrs) (11 male, 9
females) with type 2 diabetes (11 insulin-treated) were
recruited from the multidisciplinary diabetes clinic at
Torbay Hospital, a UK district general hospital in 2008.
All subjects were obese with a body mass index of
greater than 30 Kg/m2 and had expressed the desire to
lose weight. In an open design, all subjects were studied
before, during and after 6 months dietary and lifestyle
intervention and rimonabant therapy, 20 milligrams
once daily (the standard licensed dose).
At baseline, all subjects received dietary and lifestyle
advice from a specialist diabetes dietician, having com-
pleted a 5 day food diary, and were prescribed an indivi-
dualised 600-800 kcal deficit diet based on healthy
eating and portion control. Patients were followed-upduring the trial with monthly telephone consultations
and with outpatient clinic reviews at 3 and 6 months.
Patients with contraindications for the use of rimona-
bant (including depressive illness), clinical or echocar-
diographic evidence of left ventricular impairment,
peripheral vascular disease or significant renal impair-
ment (estimated GFR< 30 ml/min) were excluded. All
subjects had been receiving a stable regime of blood
glucose-lowering treatment for at least 3 months prior
to study entry. All subjects were studied at baseline and
then at 6 months following the weight loss intervention.
Study measurements and blood samples were under-
taken in the morning after a 12 hour fast and medica-
tions were omitted on the morning of study. Dietary
follow up consisted of monthly telephone calls and re-
view and analysis of the food diary at 6 months. The
telephone calls involved informal discussion with the in-
dividual patient about general well-being, tolerability of
the study medication, appetite and food intake. Patients
were given encouragement to adhere to their individua-
lised diet plan. The 5 day food diaries at baseline and at
6 months were analysed using the dietary analysis soft-
ware package, Diet Plan 6 (Forestfield Software Ltd,
UK). The 5 day food diaries were discussed with the in-
dividual patients during the baseline and 6 monthly vis-
its. A food portion Atlas [17] was used with the patient
so that the patient could identify their portion size. This
was coded by the dietitian and the amounts entered into
the Diet Plan programme.
Body composition analysis was performed using the
method of bioelectrical impedance (Tanita).
Fasting blood samples (10 ml venous blood for each
subject) were drawn on the morning of study. The study
had approval from the local research ethics committee,
together with clinical trial authorisation. All subjects
gave informed consent to participate in the study.
Statistical analysis
All statistical analyses were performed using SPSS (ver-
sion 14) for Windows. Data are expressed as mean
values ± SD. Paired t-tests were used to evaluate differ-
ences between group means in the same subjects over
time for normally distributed data. Correlation between
variables was evaluated using Spearman’s and Pearson’s
correlation coefficients. A p value of less than 0.05 was
considered significant.
Results
The study group consisted of 11 males and 9 females.
The mean age of participants was 58 ± 11 years and the
mean duration of diabetes was 7 ± 7 years. Eleven out of
20 were receiving insulin therapy. Mean Body mass
index (Kg/m2) was 38 ± 5 Kg/m2. There was 1 active
smoker in the group.
Table 2 Effects of Rimonabant with dietary intervention
on daily energy and macronutrient intake before and
after intervention (n= 18) (Mean± SD)
Variable Baseline 6 months
Energy (Kcal) 2225 ± 1109 1589± 384 **
Carbohydrate (g) 273 ± 194 199 ± 74 *
Protein (g) 98 ± 36 78 ± 23 *
Fat (g) 84 ± 39 55 ± 18 **
Starch (g) 148 ± 48 114 ± 36 *
Sugar (g) 121 ± 171 74 ± 64
Non-starch polysaccharide (g) 18 ± 5 14 ± 3 **
Saturated fatty acids (g) 30 ± 16 20 ± 6 **
Monounsaturated fatty acids (g) 29 ± 12 19 ± 7 **
Polyunsaturated fatty acids (g) 16 ± 8 10 ± 4 **
*p< 0.05 in comparison to baseline.
**p< 0.01 in comparison to baseline.
Heppenstall et al. Nutrition Journal 2012, 11:50 Page 3 of 6
http://www.nutritionj.com/content/11/1/50The effects of rimonabant on physical and biochemical
measurements are shown in Table 1. Weight was reduced
from 112± 21 Kg at baseline to 107± 21 Kg after 6 months
(p< 0.001) equating to a mean 4% weight reduction and
this was accompanied by a reduction in waist circumfer-
ence from 124± 13 cm to 121± 13 cm (p< 0.05). Nine
out of 20 patients lost more than 5% of body weight over
the 6 month treatment period and 2 out of 20 lost more
than 10% of body weight. Weight changes were associated
with a reduction in HbA1c from 8.0 ± 1.6% at baseline to
7.4 ± 1.7% at 6 months (p< 0.05). For the 11 subjects re-
ceiving insulin therapy, mean insulin dose fell from
116± 59 units/day at baseline to 102± 71 units/day after
6 months (p< 0.05). There was a rise in HDL cholesterol
from 1.2 ± 0.2 mmol/L at baseline to 1.3 ± 0.2 mmol/L at
6 months (p< 0.01).
Macronutrient intake and dietary composition
Completed and detailed dietary data using Dietplan was
available for 18 out of 20 subjects. Food diaries were
deemed incomplete and not suitable for analysis in 2
subjects. The changes in daily dietary intake of energy
and macronutrients during the study are shown in
Table 2. Six months following rimonabant treatment
daily energy intake was reduced from 2225 ± 1109 to
1589 ± 384 kcal (p< 0.01). Total carbohydrate intake was
reduced from 273 ± 194 to 199 ± 74 g (p< 0.05) with sta-
tistically significant reductions in starch (148 ± 48 versus
114 ± 36 g, p< 0.05) and non-starch polysaccharide
(18 ± 5 versus 14 ± 3 g, p< 0.01) but a non-significant re-
duction in intake of sugar (121 ± 171 versus 74 ± 64 g
(p = 0.10). Protein intake was reduced from 98 ± 36 to
78 ± 23 g (p< 0.05). Total fat intake was reduced from
84 ± 39 to 55 ± 18 g (p< 0.01) (35% reduction) withTable 1 Effects of Rimonabant with dietary intervention
on physical and biochemical parameters over the study
period (n= 20) (Mean± SD)
Baseline 6 Months
Weight (Kg) 112 ± 21 107 ± 21***
Waist circumference (cm) 124 ± 13 121 ± 13**
Fat mass (Kg) 44 ± 12 42 ± 12
HbA1c (%) 8.0 ± 1.6 7.4 ± 1.7*
Total cholesterol (mmol/L) 4.4 ± 1.0 4.4 ± 1.0
LDL cholesterol (mmol/L) 2.3 ± 0.8 2.4 ± 0.9
HDL cholesterol (mmol/L) 1.2 ± 0.2 1.3 ± 0.2**
Triglyceride (mmol/L) 1.9 ± 1.1 1.7 ± 0.9
Insulin dose (units / day) 116 ± 59 102 ± 71*
Systolic blood pressure (mmHg) 147 ± 21 142 ± 24
Diastolic blood pressure (mmHg) 85 ± 8 83 ± 11
*p< 0.05 in comparison to baseline.
**p< 0.01 in comparison to baseline.
***p< 0.001 in comparison to baseline.reductions in saturated fatty acids (30 ± 16 versus
20 ± 6 g, p< 0.01) (33% reduction), monounsaturated
fatty acids (29 ± 12 versus 19 ± 7 g, p< 0.01) (34% reduc-
tion) and polyunsaturated fatty acids (16 ± 8 versus
10 ± 4 g, p< 0.01) (38% reduction).
The dietary composition of macronutrients for the
group, expressed as a % of total energy intake at baseline
was carbohydrate 46%, fat 34% and protein 17%. After
6 months this composition had not changed significantly
with carbohydrate 47%, fat 31% and protein 18%.
Micronutrient intake
Details of daily micronutrient intake before and after
rimonabant treatment are shown in Table 3. With re-
spect to micronutrient intake, after 6 months (in com-
parison with baseline), levels of intake of sodium
(2544 ± 866 versus 3793 ± 1487 mg, p< 0.01), potassiumTable 3 Effects of Rimonabant with dietary intervention
on daily micronutrient intake before and after
intervention (n= 18) (Mean± SD)
Variable Baseline 6 months Reference Nutrient
Intakes (RNI)
Calcium (mg) 940 ± 439 725 ± 272 700
Iron (mg) 14 ± 5 11 ± 4 8.7
Females< 50 yrs 14.8
Vitamin E (mg) 8.8 ± 5 5.9 ± 3 * No RNI
Folate (μg) 431 ± 324 292 ± 103 * 200
Vitamin A (μg) 3075 ± 3610 3688± 2955 Males 700
Females 600
Vitamin C (mg) 299 ± 704 135 ± 121 40
Sodium (mg) 3793 ± 1487 2544± 866 ** 1600-2400
Potassium (mg) 4307 ± 3299 2874± 944 * 3500
*p< 0.05 in comparison to baseline.
**p< 0.01 in comparison to baseline.
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(5.9 ± 2.6 versus 8.8 ± 5.1 mg, p< 0.05) and folate
(292 ± 103 versus 431 ± 324 mg, p< 0.05) were reduced.
There was no evidence of a statistically significant
increased intake of any micronutrient studied following
the intervention. In terms of Reference Nutrient Intake
(RNI) for micronutrients, 9 of the 20 subjects did not
meet the RNI for potassium at baseline and this
increased to 15 at 6 months. No subjects over the age of
65 met the RNI for Vitamin D. With regards to calcium
intake, 7 of the 20 subjects did not meet the RNI at
baseline and 9 did not meet the RNI at 6 months. With
regards to iron intake 3 subjects did not meet the RNI at
baseline and this increased to 5 at 6 months. For vitamin
A, 4 subjects did not meet the RNI at baseline and this
increased to 5 at 6 months.
Relationship between glycaemia and dietary composition
A strong correlation was observed between the reduc-
tion in carbohydrate intake and improvement in gly-
caemic control (as indicated by change in HbA1c
concentration) over the study period (r = 0.76, p
< 0.0001). This correlation persisted after controlling for
weight loss and energy intake. Multiple stepwise regres-
sion analysis revealed carbohydrate intake to be an inde-
pendent predictor of change in HbA1c (Table 4). It was
noted that 1 individual recorded an excessively large
carbohydrate intake at baseline, which reduced dramat-
ically following the intervention. This led to a very high
change in carbohydrate intake for this individual of
around 550 g. On further enquiry, the carbohydrate in-
take was verified. Results were re-analysed excluding this
individual but the statistical relationship persisted
(r = 0.54, p< 0.05) (Figure 1). Reduction in fat intake
correlated with degree of weight loss (change in weight
from baseline to end of study) (r = 0.48, p< 0.05). In
contrast, reduction in carbohydrate intake did not cor-
relate with the degree of weight loss.
Discussion
Dietary intervention is fundamental to the control of glu-
cose and weight in obese individuals with type 2 diabetes.
Understanding how specific dietary interventions and
anti-obesity agents affect an individual’s dietary compos-
ition and energy intake should enable us to target these
interventions more effectively. In the present study weTable 4 Stepwise multiple regression analysis with
ΔHbA1c as dependent variable (R2 = 0.58)
Independent variable Beta t p value
Δ carbohydrate intake 0.76 4.7 <0.0001
Δ energy intake 0.16 0.61 0.16
Δ weight -0.26 -0.15 0.88investigated the effects of a dietary intervention involving
the use of the anti-obesity agent, rimonabant on blood
glucose, energy intake and dietary composition in obese
adults with type 2 diabetes.
The main findings of the present study were that an
individualised diet based on healthy eating and portion
control, in combination with rimonabant therapy led to
significant weight loss over a 6 month period with a ma-
jority of patients losing in excess of 5% of their body
weight. The reduction in body weight was accompanied
by a reduction in weight circumference and favourable
changes to the lipid profile and blood glucose control.
These beneficial effects on body weight and metabolic
parameters occurred in association with a significant re-
duction in energy intake, together with reductions in the
intake of the principal macronutrients, carbohydrate, fat
and protein. The levels of these macronutrients were
reduced to a similar degree such that the overall dietary
composition remained unchanged.
As well as conventional lifestyle intervention, pharmaco-
logical therapies are increasingly used to combat obesity.
Rimonabant is a cannabinoid-1 receptor blocker that
induces weight loss and improves the cardiovascular risk
profile, glycemia and insulin sensitivity in diabetic subjects
[6]. The endocannabinoid system, consisting of cannabin-
oid type 1 (CB1) receptors and endogenous ligands is
expressed widely, not only in the central nervous system
but also in peripheral organs including visceral adipose
tissue [18]. The effects of CB1 receptor blockers on
weight, energy expenditure and calorific intake have been
studied in detail in rodent models. In these studies CB1-
receptor antagonism at the hypothalamic level resulted
not only in reduced food intake but also a change in the
composition of the diet [8,9,19]. In particular, Mathes
et al. using a novel dessert protocol in female rats demon-
strated a lowered calorific consumption with reduced in-
take of palatable food (sugar fat whip) following
rimonabant treatment [19]. In addition, rimonabant has
been shown in a rodent model to enhance lipolysis in adi-
pose tissue leading to increased energy expenditure
through oxidation of fatty acids and this effect was consid-
ered an important determinant of weight loss independent
of food intake [7].
Inferences from these animal studies include the con-
tention that the endocannabinoid system is an important
modulator of the rewarding properties of foods by acting
through specific mesolimbic areas in the brain and that
CB1 receptor antagonists may have the potential in
humans to reduce the intake of hedonistic type foods in
favour of less energy-dense and healthier alternatives
[4,20]. To date these observations remain unproven in
human studies and indeed, results from our present
study are at variance with these animal studies in that
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Figure 1 Relationship between reduction in carbohydrate intake and improvement in glycaemic control (as indicated by change in
HbA1c concentration) in rimonabant-treated subjects (n = 17) (r = 0.54, p< 0.05).
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wards a healthier, less palatable diet. Instead, individuals
appeared to simply reduce calorie intake by globally re-
ducing intake of most macronutrients and several micro-
nutrients in addition. ‘Surrogate markers’ of a healthier
diet such as an increased intake of potassium or dietary
fibre were not observed and in fact levels of both these
nutrients fell following rimonabant therapy.
In the present study we observed a strong relationship
between carbohydrate intake and blood glucose levels,
with reduction in carbohydrate intake during the study
being closely correlated with reduction in glycated
haemoglobin independent of body weight change or
total energy intake. In contrast, changes in body weight
appeared to be more closely related to fat intake rather
than carbohydrate intake. These data are in keeping with
the growing body of evidence in favour of carbohydrate
restriction as a key intervention to optimise glucose con-
trol in individuals with type 2 diabetes [10,13-15].
Micronutrient intake was also assessed in the present
study. Of note, levels of several micronutrients fell fol-
lowing dietary and rimonabant therapy, paralleling the
changes observed in macronutrients. Indeed, there
appeared to be a trend for an increasing number of sub-
jects failing to meet the Reference Nutrient Intake (RNI)
for several important micronutrients following the inter-
vention. This observation appears to suggest that some
patients could be at risk of adopting a poorer quality dietfollowing this type of dietary intervention and is an area
of major concern.
Study limitations and recommendations
This study was intended to mimic that of a clinical situ-
ation as much as possible to give an insight into how
CB1 receptor antagonists impact patient’s diets and to
ascertain whether further research on CB1 receptor
antagonists and indeed other anti-obesity medication on
dietary composition is worthwhile. There are certainly
limitations to this study, namely the relatively small sam-
ple size, open design and lack of a control group. Ideally
a randomised, placebo-controlled trial would have been
the preferred study design but this was not feasible
within the resources available to us. Another alternative
would have been to study a parallel group of similar
patients who lost weight through dietary intervention
alone, without anti-obesity medication. This latter type
of study design would have significantly enhanced the
quality of this study and indeed was originally intended.
Unfortunately, it was not possible to achieve meaningful
weight loss through our dietary intervention alone in
our intended control group of type 2 diabetic patients.
Since no valid comparisons in terms of dietary changes
between rimonabant-treated patients and controls are
possible without comparable weight loss achieved in
each group, it was decided that the rimonabant-treated
patients alone would be included in the final analysis.
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employ in clinical research but it is hoped that future re-
search including larger controlled trials will be possible
to examine dietary changes induced by both centrally
acting anti-obesity drugs and other potential anti-obesity
agents such as glucagon-like-peptide-1 (GLP-1) agonists.
This is certainly an area worthy of further study given
the potential widespread application of such agents and
the knowledge gleaned from the present study suggest-
ing significant change in dietary composition associated
with CB-1 receptor antagonism. In particular, our obser-
vations that levels of some important micronutrients
may fall below recommended levels of intake following
anti-obesity medication is an area of special concern.
We would suggest that detailed dietetic input is war-
ranted in this situation to ensure that dietary intake of
essential micronutrients is not compromised during this
type of weight loss intervention.
Conclusions
Weight loss achieved following dietary intervention in
combination with rimonabant therapy occurred because
of reduced energy intake. This was associated with an
unselective reduction in intake of all the major macro-
nutrients without any change to the overall composition
of the diet. Thus, although pre-clinical studies support
the hypothesis that CB1 receptor antagonists modulate
feeding behaviour by altering the perception of palatabil-
ity, our present study does not support this hypothesis
in human subjects with type 2 diabetes.
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